可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Mebazaa A, Wetzel RC, Dodd-o JM, et al. Potential paracrine role of the pericardium in the regulation of cardiac function[J] . Cardiovasc Res, 1998, 40(2):332-342.[2] 王士雯,钱方毅. 老年心脏病学[M]. 第2版. 北京: 人民卫生出版社, 1998:556-566.[3] Parlapiano C, Paoletti V, Campana E, et al. CGRP and ET-1 plasma levels in normal subjects[J]. Eur Rev Med Pharmacol, 1999, 3(3):139-141.[4] 陈良海, 罗兴林, 李刚. 降钙素基因相关肽和内皮素在充血性心力衰竭中的作用[J]. 临床心血管病杂志, 1998, 14(3):146-147.[5] Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future[J]. Circ Res, 2002, 91(11):988-998.[6] Torre-Amione G, Young JB, Durand J, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class Ⅲ to Ⅳ congestive heart failure[J]. Circulation, 2001, 103(7):973-980.[7] 温绍君,王耀宏,王卫梅,等. 心脏病患者心功能与心包液中心钠素和内皮素浓度的关系[J]. 中华心血管病杂志, 2000, 28(5):377-378.[8] Bucinskaite V, Brodda-Jansen G, Stenfors C, et al. Increased concentrations of Calcitonin gene-related peptide-like immunoreactivity in rat brain and peripheral tissue after ischaemia: correlation to flap survival[J]. Neuropeptides, 1998, 32(2):179-183.[9] Filippelli A, Falciani M, Piucci B, et al. Endothelin-1 affects capsaicin-evoked release of neuropeptides from rat vas deferens[J]. Eur J Pharmacol, 1999, 364(2-3):183-191.